186 results
424B3
PRTG
Portage Biotech Inc.
27 Aug 24
Prospectus supplement
6:11am
the Company’s ability to attract, retain and motivate key employees, and expose the Company to potential litigation in connection with this process … to attract, retain and motivate key employees, and expose us to potential litigation in connection with this process or any resulting transaction. If we
6-K
EX-99.1
PRTG
Portage Biotech Inc.
27 Aug 24
Current report (foreign)
6:05am
employees, and expose the Company to potential litigation in connection with this process or any resulting transaction. If the Company is unable
6-K
EX-99.2
PRTG
Portage Biotech Inc.
27 Aug 24
Current report (foreign)
6:05am
and motivate key employees, and expose us to potential litigation in connection with this process or any resulting transaction. If we are unable
POS AM
PRTG
Portage Biotech Inc.
22 Aug 24
Prospectus update (post-effective amendment)
6:24pm
This prospectus contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements … rights, including patents, litigation matters and our ability to obtain patent protection for our products;
the recruitment or departure of key
424B3
3bo6gf2q
6 Mar 24
Prospectus supplement
9:36pm
6-K
EX-99.1
89srv5o lr6lh1r
6 Mar 24
Current report (foreign)
9:11pm
6-K
EX-99.1
v6f2r4j91o4d g9x
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
424B3
37xzqwfe88 2il
18 Jan 24
Prospectus supplement
5:41pm
6-K
EX-99.1
8mwcskekx3ayxvfe
18 Jan 24
Current report (foreign)
5:09pm
424B3
mlzx1
7 Nov 23
Prospectus supplement
4:50pm
F-1
mkonm74x hnq
31 Oct 23
Registration statement (foreign)
4:05pm
6-K
EX-10.1
9pk2fxudrrpuxl8n
3 Oct 23
Current report (foreign)
4:05pm
424B5
u3glzm70sfh35tlci
2 Oct 23
Prospectus supplement for primary offering
6:01pm
424B5
6azuq
19 Aug 22
Prospectus supplement for primary offering
10:52am
6-K
EX-2.1
robq34
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am